Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | GIPR | P48546 | 1/20 | 0.43 |
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.38 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387849 | 0.89 | GCGR (0.63) | GCGRGLP1RGIPR | |
| SCHEMBL5360807 | 0.88 | GCGR (0.58) | GCGRGLP1RGIPR | |
| SCHEMBL5360803 | 0.88 | GCGR (0.58) | GCGRGLP1RGIPR | |
| SCHEMBL14535135 | 0.83 | GCGR (0.49) | GCGRGLP1RGIPR | |
| SCHEMBL14387758 | 0.83 | GCGR (0.49) | GCGRGLP1RGIPR | |
| SCHEMBL14387974 | 0.82 | GCGR (0.62) | GCGRGLP1RGIPR | |
| SCHEMBL14387942 | 0.80 | GCGR (0.43) | GCGR | |
| SCHEMBL14387857 | 0.80 | GCGR (0.53) | GCGRGLP1RGIPR | |
| SCHEMBL14387926 | 0.79 | GCGR (0.50) | GCGRGLP1RGIPR | |
| SCHEMBL14356420 | 0.79 | GCGR (0.65) | GCGRGLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301036-B2 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | GCGR 1/4885GLP1R 2/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.